Business Standard

Alembic Pharmaceuticals Share Price

Know More

938.00 2.95 (0.32%)

12:00 AM,19th Apr 2024

938.35 7.30 (0.78%)

12:00 AM,19th Apr 2024

BSE : 533573


Sector : Health care

ISIN Code : INE901L01018

  • BSE
  • NSE
  • 1D
  • 5D
  • 1M
  • 6M
  • 1Y
  • 2Y
  • 5Y
  • MAX

Last Updated: 19-Apr-2024 | 12:00 AM IST

Market Cap (₹ Cr)


Turnover (₹ Cr)


Volume (Shares)


Face Value


52-WK High


52-WK High Date


52-WK Low


52-WK Low Date


All Time High


All Time High Date


All Time Low


All Time Low Date


Alembic Pharmaceuticals Ltd

Alembic Pharmaceuticals manufactures and markets generic pharmaceutical products all over the world. The company's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the US FDA. The company is one of the leaders in branded generics in India. Alembic Pharmaceuticals Ltd was incorporated on June 16 2010 as a wholly owned subsidiary of Alembic Ltd. The company is engaged in pharmaceuticals business. As per the scheme of arrangement the 'Pharmaceutical Undertaking' of the Alembic Ltd was demerged and transferred to the company with effect from appointed date April 1 2010. In April 15 2011 the company ceased to be a ...
Read More

Alembic Pharma Announcement

<b>Format of the Annual Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px> <tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr> <td>1</td> <td>Name of Company</td> <td>ALEMBIC PHARMACEUTICALS LTD.</td> </tr> <tr> <td>2</td> <td>CIN NO.</td> <td>L24230GJ2010PLC061123</td> </tr> <tr> <td>3</td> <td>Report filed for FY</td> <td>2023-2024</td> </tr> <tr><td colspan=3>Details of the Current block (all figures in Rs crore):</td><tr> <tr> <td>4</td> <td>2 - year block period (Specify financial years)* </td> <td>2023-24 2024-25</td> </tr> <tr> <tr> <td>5</td> <td>Incremental borrowing done in FY (T)(a) </td> <td>0.00</td> </tr> <tr> <td>6</td> <td>Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a)</td> <td>0.00</td> </tr> <tr> <td>7</td> <td>Actual borrowing done through debt securities in FY (T)(c)</td> <td>0.00</td> </tr> <tr> <td>8</td> <td> Shortfall in the borrowing through debt securities if any for FY (T - 1) carried forward to FY (T) (d)</td> <td>Not Applicable</td> </tr> <tr> <td>8</td><td>Quantum of (d) which has been met from (c)(e)*</td> <td>Not Applicable</td> </tr><tr> <td>9</td><td> Shortfall if any in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T - 1) which was carried forward to FY(T)}(f) = (b) - [(c) - (e)]{ If the calculated value is zero or negative write nil}*</td> <td>Not Applicable</td> </tr> </table> <br/><br/><table><tr><td colspan=2><b>Details of penalty to be paid if any in respect to previous block (all figures in Rs crore):</b></td></tr> <tr><td>2 - year Block period (Specify financial years)</td><td>2022-23 2023-24</td></tr> <tr><td>Amount of fine to be paid for the block if applicable Fine = 0.2% of {(d) - (e)}#</td><td>0.00</td></tr> </table> <div> <br/><br/><br/> <table><tr><td>Name of the Company Secretary :-</td><td>Manisha Saraf</td></tr><tr><td>Designation :-</td><td>Company Secretary</td></tr> <tr><td>Name of the Chief Financial Officer :- </td><td>Rajkumar Baheti</td></tr> <tr><td>Designation : -</td><td>Director Finance and CFO</td></tr></table><div> <br/> Date: 19/04/2024<br/><br/></div>

<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>ALEMBIC PHARMACEUTICALS LTD.</td></tr> <tr><td>2</td><td>CIN NO.</td><td>L24230GJ2010PLC061123</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)</td> <td>0.00</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>AA+</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>CRISIL LTD.</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework</td><td>NSE</td></tr> </table> <br/><br/> <div> <div style=float:left;> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No</div> <br/><br/><br/> <div style=float:left;> Name of the Company Secretary: Manisha Saraf <br/> Designation: Company Secretary <br/> EmailId:</div> <div style=float:left;margin-left:50px;> Name of the Chief Financial Officer: Rajkumar Baheti <br/> Designation: Director Finance and CFO <br/> EmailId:</div> </div> <div> <br/> Date: 19/04/2024<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div>

View More

Alembic Pharmaceuticals Ltd - Key Fundamentals

Market Cap (₹ Cr)


EPS - TTM (₹) [S]


P/E Ratio (X) [S]


Face Value (₹) 2
Latest Dividend (%)400.00
Latest Dividend Date 28-Jul-2023
Dividend Yield (%) 0.85
Book Value Share (₹) [S]228.24
P/B Ratio (₹) [S]4.11

Funds Owing this Stock

Scheme Name Amount Invested (₹ Cr) No Of Shares Net Asset (%)
Canara Robeco Conservative Hybrid Fund (IDCW-M) 3.15 32,500 0.32
Canara Robeco Conservative Hybrid Fund (G) 3.15 32,500 0.32
Canara Robeco Conservative Hybrid Fund (IDCW-Q) 3.15 32,500 0.32
Canara Robeco Conservative Hybrid Fund-Dir(IDCW-M) 3.15 32,500 0.32
Canara Robeco Conservative Hybrid Fund-Dir(IDCW-Q) 3.15 32,500 0.32
Canara Robeco Conservative Hybrid Fund-Dir (G) 3.15 32,500 0.32

Research Reports

Date Broker Action Prices(₹) Report
Data Not Found

Stock Strength

Today's Low/High



Week Low/High



Month Low/High



Year Low/High



All time Low/High



Share Price Returns

1 Week-4.68%-4.50%-1.56-1.65%
1 Month0.43%0.47%1.491.51%
3 Month-0.48%-0.54%1.962.43%
6 Month16.24%16.07%11.3712.85%
1 Year77.16%77.00%22.7025.70%
3 Year-6.17%-6.00%52.4354.23%

Company Info

Company Information

Chairman and MD & CEO : Chirayu R Amin

Independent Director : Pranav N Parikh

Independent Director : K G Ramanathan

Independent Director : Paresh Saraiya

Director & CFO : Rajkumar Baheti

Independent Director : Milin Mehta

Managing Director : Pranav Amin

Managing Director : Shaunak Amin

Independent Director : Archana Hingorani

Company Secretary : Charandeep Singh Saluja

Registered Office: Alembic Road, ,Vadodara,Gujarat-390003 Ph: 91-0265-2280550